BACKGROUND: Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic breast cancer who had received prior chemotherapy for their met...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!